Semantelli releases AETracker to help pharma stay on Facebook.
Mount Arlington, NJ August 7, 2011 – Semantelli Corporation announced today the release of Facebook AETracker - a unique solution to help pharmaceutical companies maintain Facebook pages after the August 15th deadline imposed by the social networking giant. In May this year, Facebook announced that it will enable public feedback and comments to encourage bidirectional dialogue on pages created by pharmaceutical companies, ending an exclusive privilege it had given pharma for years.
Facebook AETracker helps pharma companies track Adverse Events and Product Misinformation in user comments on company sponsored Facebook pages in real-time with additional workflow to report them to FDA.
“Our ability to track Adverse Events, Product Misinformation and other potential threats real-time using Semantic Web technology in Facebook, Twitter and other social media channels should make FDA happy. This allows pharma companies stay on Facebook, and at the same time frees them to further explore the power of social media without waiting for guidelines or fearing regulatory impacts. Social Media is just another channel. We should treat it as such. It can play a major role in improving health outcome.” said Siva Nadarajah CEO of Semantelli.
In addition to identifying Adverse Events and Misinformation, the Semantelli product will also spot possible threats that may impact the reputation of a company.
“This is a natural addition to our enterprise reputation platform. Recent hacks on pharma Facebook pages is a clear example that tools that can spot threats are necessary to augment human moderation. Our offering is an end-to-end real-time solution that combines technology with traditional moderation” added Siva Nadarajah.
About Semantelli
Semantelli is the leader in Semantic Web based enterprise listening solutions for the global life sciences industry. Companies use Semantelli’s compliance sensitive solutions to monitor social media, web and internal unstructured data sources to find previously unknown early warnings, threats and opportunities. Semantelli customers have found immediate ROI, ranging from spotting threats, new trends, targeted promotions and engaging doctors who have shown signs of switching to competitor brands. Semantelli is a privately held start-up headquartered in Mount Arlington, NJ. For more information visit http://www.semantelli.com/pharma/facebook_aetracker
Contacts
pr@semantelli.com
1-908-547-0205
In:
